Drug intelligence / Profile preview

HGP0508

Development stage: Preclinical
Lead developer: HitGen
Modality: Small Molecules
Administration: Oral

Overview

HGP0508 is an orally bioavailable small molecule inhibitor of interleukin-17A (IL-17A) being developed by HitGen Inc. for the treatment of inflammatory and autoimmune diseases. Discovered using HitGen's proprietary DNA-encoded library (DEL) technology platform, HGP0508 represents an innovative approach to targeting the IL-17 pathway, which is currently dominated by injectable monoclonal antibody therapies. Preclinical studies have indicated that HGP0508 possesses in vivo activity comparable to that of established antibody treatments. The program is currently in the preclinical development stage, with efforts focused on advancing the compound toward an Investigational New Drug (IND) filing.

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on HGP0508.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP0508.

Explore the full profile